B

BenevolentAI

Creating Life-Changing Medicines with AI

London, UK (US presence)
350+

About BenevolentAI

Industry: AI Drug Discovery
Founded: 2013
Founders: Ken Sheridan, Jackie Hunter
Status: Public (AMS: BAI)

Funding & Growth

Total Raised: $500M+
Valuation: $1B+
Stage: Public
Key Investors:
Temasek Woodford Investment Lansdowne Partners

✓ Pros

  • • Pioneer in AI drug discovery
  • • Knowledge graph technology
  • • AstraZeneca partnership
  • • Good European work culture
  • • Published research

✗ Cons

  • • Stock volatility
  • • UK-centric (limited US roles)
  • • Pre-revenue drug discovery
  • • Long timelines to validation

Get weekly job alerts